

# Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth (Status and Outlook) 2024-2030

<https://marketpublishers.com/r/G3124B83F43CEN.html>

Date: January 2024

Pages: 90

Price: US\$ 3,660.00 (Single User License)

ID: G3124B83F43CEN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market size was valued at US\$ million in 2023. With growing demand in downstream market, the ESR1 Mutated Metastatic Breast Cancer Diagnostics is forecast to a readjusted size of US\$ million by 2030 with a CAGR of % during review period.

The research report highlights the growth potential of the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market. ESR1 Mutated Metastatic Breast Cancer Diagnostics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of ESR1 Mutated Metastatic Breast Cancer Diagnostics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the ESR1 Mutated Metastatic Breast Cancer Diagnostics market.

### Key Features:

The report on ESR1 Mutated Metastatic Breast Cancer Diagnostics market reflects various aspects and provide valuable insights into the industry.

**Market Size and Growth:** The research report provide an overview of the current size and growth of the ESR1 Mutated Metastatic Breast Cancer Diagnostics market. It may

include historical data, market segmentation by Type (e.g., NGS Based, PCR Based), and regional breakdowns.

**Market Drivers and Challenges:** The report can identify and analyse the factors driving the growth of the ESR1 Mutated Metastatic Breast Cancer Diagnostics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

**Competitive Landscape:** The research report provides analysis of the competitive landscape within the ESR1 Mutated Metastatic Breast Cancer Diagnostics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

**Technological Developments:** The research report can delve into the latest technological developments in the ESR1 Mutated Metastatic Breast Cancer Diagnostics industry. This include advancements in ESR1 Mutated Metastatic Breast Cancer Diagnostics technology, ESR1 Mutated Metastatic Breast Cancer Diagnostics new entrants, ESR1 Mutated Metastatic Breast Cancer Diagnostics new investment, and other innovations that are shaping the future of ESR1 Mutated Metastatic Breast Cancer Diagnostics.

**Downstream Procumbent Preference:** The report can shed light on customer procumbent behaviour and adoption trends in the ESR1 Mutated Metastatic Breast Cancer Diagnostics market. It includes factors influencing customer ' purchasing decisions, preferences for ESR1 Mutated Metastatic Breast Cancer Diagnostics product.

**Government Policies and Incentives:** The research report analyse the impact of government policies and incentives on the ESR1 Mutated Metastatic Breast Cancer Diagnostics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting ESR1 Mutated Metastatic Breast Cancer Diagnostics market. The report also evaluates the effectiveness of these policies in driving market growth.

**Environmental Impact and Sustainability:** The research report assess the environmental impact and sustainability aspects of the ESR1 Mutated Metastatic Breast Cancer Diagnostics market.

**Market Forecasts and Future Outlook:** Based on the analysis conducted, the research report provide market forecasts and outlook for the ESR1 Mutated Metastatic Breast Cancer Diagnostics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

**Recommendations and Opportunities:** The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the ESR1 Mutated Metastatic Breast Cancer Diagnostics market.

**Market Segmentation:**

ESR1 Mutated Metastatic Breast Cancer Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

**Segmentation by type**

NGS Based

PCR Based

**Segmentation by application**

Hospital Associated Labs

Independent Diagnostic Laboratories

Diagnostic Imaging Centers

Cancer Research Institutes

This report also splits the market by region:

## Americas

United States

Canada

Mexico

Brazil

## APAC

China

Japan

Korea

Southeast Asia

India

Australia

## Europe

Germany

France

UK

Italy

Russia

## Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

APIS Assay Technologies

Illumina, Inc.

GENCURIX

RainSure Scientific

NeoGenomics Laboratories

Sysmex Corporation

ASURAGEN,INC

Guardant Health

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2019-2030
  - 2.1.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Region 2019 VS 2023 VS 2030
- 2.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Type
  - 2.2.1 NGS Based
  - 2.2.2 PCR Based
- 2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type
  - 2.3.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Type (2019 VS 2023 VS 2030)
  - 2.3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2019-2024)
- 2.4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Application
  - 2.4.1 Hospital Associated Labs
  - 2.4.2 Independent Diagnostic Laboratories
  - 2.4.3 Diagnostic Imaging Centers
  - 2.4.4 Cancer Research Institutes
- 2.5 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application
  - 2.5.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Application (2019 VS 2023 VS 2030)
  - 2.5.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2019-2024)

### **3 ESR1 MUTATED METASTATIC BREAST CANCER DIAGNOSTICS MARKET SIZE BY PLAYER**

3.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Players

3.1.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Players (2019-2024)

3.1.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Players (2019-2024)

3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

### **4 ESR1 MUTATED METASTATIC BREAST CANCER DIAGNOSTICS BY REGIONS**

4.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Regions (2019-2024)

4.2 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2019-2024)

4.3 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2019-2024)

4.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2019-2024)

4.5 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2019-2024)

### **5 AMERICAS**

5.1 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)

5.2 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2019-2024)

5.3 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## **6 APAC**

6.1 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2019-2024)

6.2 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2019-2024)

6.3 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2019-2024)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

## **7 EUROPE**

7.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics by Country (2019-2024)

7.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2019-2024)

7.3 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics by Region (2019-2024)

8.2 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2019-2024)



### 8.3 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## 9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## 10 GLOBAL ESR1 MUTATED METASTATIC BREAST CANCER DIAGNOSTICS MARKET FORECAST

10.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Regions (2025-2030)

10.1.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Regions (2025-2030)

10.1.2 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast

10.1.3 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast

10.1.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast

10.1.5 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast

10.2 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Country (2025-2030)

10.2.1 United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.2.2 Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.2.3 Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.2.4 Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.3 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Region (2025-2030)

10.3.1 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.3.2 Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.3.3 Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.3.4 Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market

## Forecast

10.3.5 India ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.3.6 Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Country (2025-2030)

10.4.1 Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.4.2 France ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.4.3 UK ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.4.4 Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.4.5 Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.5 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Region (2025-2030)

10.5.1 Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.5.2 South Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market

## Forecast

10.5.3 Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.5.4 Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast

10.5.5 GCC Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Market

## Forecast

10.6 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Type (2025-2030)

10.7 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Application (2025-2030)

## 11 KEY PLAYERS ANALYSIS

### 11.1 APIS Assay Technologies

11.1.1 APIS Assay Technologies Company Information

11.1.2 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

11.1.3 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)

11.1.4 APIS Assay Technologies Main Business Overview

11.1.5 APIS Assay Technologies Latest Developments

### 11.2 Illumina, Inc.

11.2.1 Illumina, Inc. Company Information

11.2.2 Illumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

11.2.3 Illumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue,

## Gross Margin and Market Share (2019-2024)

11.2.4 Illumina, Inc. Main Business Overview

11.2.5 Illumina, Inc. Latest Developments

## 11.3 GENCURIX

11.3.1 GENCURIX Company Information

11.3.2 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

11.3.3 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)

11.3.4 GENCURIX Main Business Overview

11.3.5 GENCURIX Latest Developments

## 11.4 RainSure Scientific

11.4.1 RainSure Scientific Company Information

11.4.2 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

11.4.3 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)

11.4.4 RainSure Scientific Main Business Overview

11.4.5 RainSure Scientific Latest Developments

## 11.5 NeoGenomics Laboratories

11.5.1 NeoGenomics Laboratories Company Information

11.5.2 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

11.5.3 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)

11.5.4 NeoGenomics Laboratories Main Business Overview

11.5.5 NeoGenomics Laboratories Latest Developments

## 11.6 Sysmex Corporation

11.6.1 Sysmex Corporation Company Information

11.6.2 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

11.6.3 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)

11.6.4 Sysmex Corporation Main Business Overview

11.6.5 Sysmex Corporation Latest Developments

## 11.7 ASURAGEN,INC

11.7.1 ASURAGEN,INC Company Information

11.7.2 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

11.7.3 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics  
Revenue, Gross Margin and Market Share (2019-2024)

11.7.4 ASURAGEN,INC Main Business Overview

11.7.5 ASURAGEN,INC Latest Developments

11.8 Guardant Health

11.8.1 Guardant Health Company Information

11.8.2 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product  
Offered

11.8.3 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics  
Revenue, Gross Margin and Market Share (2019-2024)

11.8.4 Guardant Health Main Business Overview

11.8.5 Guardant Health Latest Developments

## **12 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Region (2019 VS 2023 VS 2030) & (\$ Millions)

Table 2. Major Players of NGS Based

Table 3. Major Players of PCR Based

Table 4. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Type (2019 VS 2023 VS 2030) & (\$ Millions)

Table 5. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2019-2024) & (\$ Millions)

Table 6. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2019-2024)

Table 7. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Application (2019 VS 2023 VS 2030) & (\$ Millions)

Table 8. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2019-2024) & (\$ Millions)

Table 9. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2019-2024)

Table 10. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Players (2019-2024) & (\$ Millions)

Table 11. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Player (2019-2024)

Table 12. ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Head office and Products Offered

Table 13. ESR1 Mutated Metastatic Breast Cancer Diagnostics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)

Table 14. New Products and Potential Entrants

Table 15. Mergers & Acquisitions, Expansion

Table 16. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Regions 2019-2024 & (\$ Millions)

Table 17. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Regions (2019-2024)

Table 18. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country/Region (2019-2024) & (\$ millions)

Table 19. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Country/Region (2019-2024)

Table 20. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size

by Country (2019-2024) & (\$ Millions)

Table 21. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Country (2019-2024)

Table 22. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2019-2024) & (\$ Millions)

Table 23. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2019-2024)

Table 24. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2019-2024) & (\$ Millions)

Table 25. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2019-2024)

Table 26. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2019-2024) & (\$ Millions)

Table 27. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region (2019-2024)

Table 28. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2019-2024) & (\$ Millions)

Table 29. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2019-2024)

Table 30. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2019-2024) & (\$ Millions)

Table 31. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2019-2024)

Table 32. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024) & (\$ Millions)

Table 33. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Country (2019-2024)

Table 34. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2019-2024) & (\$ Millions)

Table 35. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2019-2024)

Table 36. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2019-2024) & (\$ Millions)

Table 37. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2019-2024)

Table 38. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2019-2024) & (\$ Millions)

Table 39. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region (2019-2024)

Table 40. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2019-2024) & (\$ Millions)

Table 41. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2019-2024)

Table 42. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2019-2024) & (\$ Millions)

Table 43. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2019-2024)

Table 44. Key Market Drivers & Growth Opportunities of ESR1 Mutated Metastatic Breast Cancer Diagnostics

Table 45. Key Market Challenges & Risks of ESR1 Mutated Metastatic Breast Cancer Diagnostics

Table 46. Key Industry Trends of ESR1 Mutated Metastatic Breast Cancer Diagnostics

Table 47. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Regions (2025-2030) & (\$ Millions)

Table 48. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share Forecast by Regions (2025-2030)

Table 49. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Type (2025-2030) & (\$ Millions)

Table 50. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Application (2025-2030) & (\$ Millions)

Table 51. APIS Assay Technologies Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors

Table 52. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

Table 53. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 54. APIS Assay Technologies Main Business

Table 55. APIS Assay Technologies Latest Developments

Table 56. Illumina, Inc. Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors

Table 57. Illumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

Table 58. Illumina, Inc. Main Business

Table 59. Illumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 60. Illumina, Inc. Latest Developments

Table 61. GENCURIX Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors

Table 62. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

Table 63. GENCURIX Main Business

Table 64. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 65. GENCURIX Latest Developments

Table 66. RainSure Scientific Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors

Table 67. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

Table 68. RainSure Scientific Main Business

Table 69. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 70. RainSure Scientific Latest Developments

Table 71. NeoGenomics Laboratories Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors

Table 72. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

Table 73. NeoGenomics Laboratories Main Business

Table 74. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 75. NeoGenomics Laboratories Latest Developments

Table 76. Sysmex Corporation Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors

Table 77. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

Table 78. Sysmex Corporation Main Business

Table 79. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 80. Sysmex Corporation Latest Developments

Table 81. ASURAGEN,INC Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors

Table 82. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered

Table 83. ASURAGEN,INC Main Business

Table 84. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 85. ASURAGEN,INC Latest Developments

Table 86. Guardant Health Details, Company Type, ESR1 Mutated Metastatic Breast



Cancer Diagnostics Area Served and Its Competitors

Table 87. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics  
Product Offered

Table 88. Guardant Health Main Business

Table 89. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics  
Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 90. Guardant Health Latest Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1. ESR1 Mutated Metastatic Breast Cancer Diagnostics Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate 2019-2030 (\$ Millions)
- Figure 6. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 7. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Market Share by Country/Region (2023)
- Figure 8. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 9. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type in 2023
- Figure 10. ESR1 Mutated Metastatic Breast Cancer Diagnostics in Hospital Associated Labs
- Figure 11. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Hospital Associated Labs (2019-2024) & (\$ Millions)
- Figure 12. ESR1 Mutated Metastatic Breast Cancer Diagnostics in Independent Diagnostic Laboratories
- Figure 13. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Independent Diagnostic Laboratories (2019-2024) & (\$ Millions)
- Figure 14. ESR1 Mutated Metastatic Breast Cancer Diagnostics in Diagnostic Imaging Centers
- Figure 15. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Diagnostic Imaging Centers (2019-2024) & (\$ Millions)
- Figure 16. ESR1 Mutated Metastatic Breast Cancer Diagnostics in Cancer Research Institutes
- Figure 17. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Cancer Research Institutes (2019-2024) & (\$ Millions)
- Figure 18. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application in 2023
- Figure 19. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Player in 2023

Figure 20. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Regions (2019-2024)

Figure 21. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2019-2024 (\$ Millions)

Figure 22. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2019-2024 (\$ Millions)

Figure 23. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2019-2024 (\$ Millions)

Figure 24. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2019-2024 (\$ Millions)

Figure 25. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Value Market Share by Country in 2023

Figure 26. United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 27. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 28. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 29. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 30. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region in 2023

Figure 31. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type in 2023

Figure 32. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application in 2023

Figure 33. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 34. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 35. Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 36. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 37. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 38. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 39. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size

Market Share by Country in 2023

Figure 40. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2019-2024)

Figure 41. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2019-2024)

Figure 42. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 43. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 44. UK ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 45. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 46. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 47. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region (2019-2024)

Figure 48. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2019-2024)

Figure 49. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2019-2024)

Figure 50. Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 51. South Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 52. Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 53. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 54. GCC Country ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2019-2024 (\$ Millions)

Figure 55. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 56. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 57. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 58. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 59. United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 60. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 61. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 62. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 63. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 64. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 65. Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 66. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 67. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 68. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 69. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 70. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 71. UK ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 72. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 73. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 74. Spain ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 75. Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 76. South Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 77. Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 78. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size

2025-2030 (\$ Millions)

Figure 79. GCC Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2025-2030 (\$ Millions)

Figure 80. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share Forecast by Type (2025-2030)

Figure 81. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share Forecast by Application (2025-2030)

## I would like to order

Product name: Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth (Status and Outlook) 2024-2030

Product link: <https://marketpublishers.com/r/G3124B83F43CEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3124B83F43CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

